Tumor assessment criteria in phase I trials: beyond RECIST.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Tumor Growth Rate After Nadir Is Associated With Survival in Patients WithJCO precision oncology · 2021
   Article
2. Tumor volume dynamics and tumor growth rate inEuropean journal of radiology open · 2020
   Article
3. Diffusion MRI of cancer: From low to high b-values.Journal of magnetic resonance imaging : JMRI · 2019
   Review
4. Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm.European journal of radiology · 2018
   Article
5. Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test.Molecular oncology · 2015
   Review
6. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014
   Article
7. Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.Cancer · 2013
   Article

Corrections and comments

• Commented on by
  Reply to A. Levy et al.2013
• Comment on
  Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies.2012

Authors and funding

7 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as